SELLAS Life Sciences Group Inc (NAS:SLS)
$ 1.2 -0.02 (-1.64%) Market Cap: 69.59 Mil Enterprise Value: 53.14 Mil PE Ratio: 0 PB Ratio: 7.09 GF Score: 41/100

Sellas Life Sciences Group Inc Provides Business Update and First Quarter 2022 Highlights Transcript

Apr 06, 2022 / 12:30PM GMT
Release Date Price: $3.73 (-4.11%)
Allison Soss
Kanan, Corbin, Schupak & Aronow, Inc. - SVP of IR

Okay. Let us begin with the forward-looking statement itself. Good morning, everyone, and welcome to SELLAS shareholder update call. I'm Allison Soss, Senior Vice President, KCSA Strategic Communication.

Before we begin, I would like to remind you that SELLAS will be making statements on today's call related to future expectations regarding the clinical development of its clinical candidate, GPS and GFH009, the potential for GPS and GFH009 as drug development candidates for various cancer indications, alone and in combination with other therapeutic agents, and the timing regarding data analysis, as well as the company's financials and its corporate strategy. These statements constitute forward-looking statements for the purpose of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995, and by their nature, involve estimates, projections, goals, forecasts and assumptions, and are subject to risks and uncertainties, which include, without limitation, risks and uncertainties associated with the COVID

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot